Varicella is a self-limiting and relatively mild disease of childhood, although it is frequently more severe and complicated among the immunocompromised rheumatology patients on immunomodulator therapies. In addition, future reactivation of the dormant virus in dorsal root ganglia may cause herpes zoster infection, which can be very debilitating. In this manuscript, we discuss the nature of this infection along with its potential vaccine especially among rheumatology patients.
Quinlivan M, Hawrami K, Barrett-Muir W, Aaby P, Arvin A, Chow VT et al (2002) The molecular epidemiology of varicella-zoster virus: evidence for geographic segregation. J Infect Dis 186(7):888–894PubMedCrossRefGoogle Scholar
Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A (1975) Development of a live attenuated varicella vaccine. Biken J 18(1):25–33PubMedGoogle Scholar
American Academy of Pediatrics Committee on Infectious Diseases (1995) Recommendations for the use of live attenuated varicella vaccine. Pediatrics 95(5):791–796Google Scholar
Thiry N, Beutels P, Van Damme P, Van Doorslaer E (2003) Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 21(1):13–38PubMedCrossRefGoogle Scholar
Thomas SL, Wheeler JG, Hall AJ (2002) Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 360(9334):678–682PubMedCrossRefGoogle Scholar
Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G (2000) Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 125(3):651–669PubMedCrossRefGoogle Scholar
Brisson M, Edmunds WJ, Gay NJ (2003) Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 70(Suppl 1):S31–S37PubMedCrossRefGoogle Scholar